The Centers for Medicare and Medicaid Services is requesting information from manufacturers of high-cost hepatitis C drugs on the value-based purchasing arrangements they have with payers so it can facilitate use of such arrangements in Medicaid.
In a Nov. 5 letter sent to Gilead Sciences Inc., AbbVie Inc., Johnson & Johnson...